Journal of Forensic and Legal Medicine
Volume 14, Issue 7 , Pages 389-397 , October 2007

Changing times: DNA resequencing and the “nearly normal autopsy”

  • Steven B. Karch, MD (Consultant Cardiac Pathologist/Toxicologist)

      Affiliations

    • Corresponding Author InformationTel.: +1 510 849 0623; fax: +1 510 849 0958.

Received 10 January 2006 ,Revised 30 March 2007 ,Accepted 12 April 2007.

References 

  1. Greenhalgh T. The human genome project. J R Soc Med. Dec. 2005;98(12):545
  2. Virmani R, Burke AP, Farb A. Sudden cardiac death. Cardiovasc Pathol. 2001;10(5):211–218
  3. Eckart RE, Scoville SL, Campbell CL, et al. Sudden death in young adults: a 25-year review of autopsies in military recruits. Ann Intern Med. 2004;141(11):829–834
  4. Puranik R, Chow CK, Duflou JA, Kilborn MJ, McGuire MA. Sudden death in the young. Heart Rhythm Dec. 2005;2(12):1277–1282
  5. Chugh SS, Senashova O, Watts A, et al. Postmortem molecular screening in unexplained sudden death. J Am Coll Cardiol. 2004;43(9):1625–1629
  6. Lunetta P, Levo A, Laitinen PJ, Fodstad H, Kontula K, Sajantila A. Molecular screening of selected long QT syndrome (LQTS) mutations in 165 consecutive bodies found in water. Int J Legal Med. 2003;117(2):115–117
  7. Arnested M, Crotti L, et al. Prevalence of long-QT syndrome gene variants in sudden infant death syndrome. Circulation. 2007;115(3):361–367
  8. Wang DW, Desai RR, et al. Cardiac sodium channel dysfunction in sudden infant death syndrome. Circulation. 2007;115(3):368–376
  9. Berul CI, Perry JC. Contribution of long-QT syndrome genes to sudden infant syndrome: is it time to consider newborn electrocardiographic screening?. Circulation. 2007;115(3):294–296
  10. Krahn AD, Gollob M, Yee R, et al. Diagnosis of unexplained cardiac arrest: role of adrenaline and procainamide infusion. Circulation. 2005;112(15):2228–2234
  11. Crotti L, Matteo S, Stramba-Badiale M, et al. Prevalence of the long QT syndrome. Circulation. 2005;112(17):II–660
  12. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference. Heart Rhythm. 2005;2(4):429–440
  13. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J. 1958;20(1):1–8
  14. Fokstuen S, Lyle R, Munoz A, et al. A 12 gene DNA resequencing chip for fast and reliable molecular diagnosis of hypertrophic cardiomyopathy. Circulation. 2005;112(17):II–188
  15. Jannetto PJ, Laleli-Sahin E, Wong SH. Pharmacogenomic genotyping methodologies. Clin Chem Lab Med. 2004;42(11):1256–1264
  16. Roberts R. Disrobing the emperor (heart) without destroying the dignity of super-normality. Circulation. 105:2934–2936.
  17. Brito D, Richard P, Isnard R, Pipa J, Komajda M, Madeira H. Familial hypertrophic cardiomyopathy: the same mutation, different prognosis. Comparison of two families with a long follow-up. Rev Port Cardiol. 2003;22(12):1445–1461
  18. Hughes SE, McKenna WJ. New insights into the pathology of inherited cardiomyopathy. Heart. 2005;91(2):257–264
  19. Fineschi V, Riezzo I, Centini F, et al. Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders. Int J Legal Med. 2005;(November 15):1–6
  20. Watkins H, McKenna W, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. 1995;332(16):1058–1064
  21. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. Jama. 2003;289(16):2120–2127
  22. Roden DM. Pharmacogenetics and drug-induced arrhythmias. Cardiovasc Res. 2001;50(2):224–231
  23. Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initiated by premature extrasystoles originating from the right ventricular outflow tract. J Am Coll Cardiol. 2005;46(7):1288–1294
  24. Fernandez P, Moolman-Smook J, Brink P, Corfield V. A gene locus for progressive familial heart block type II (PFHBII) maps to chromosome 1q32.2–q32.3. Hum Genet. 2005;118(1):133–137
  25. Cerrone M, Noujaim S, Jalife J. The short QT syndrome as a paradigm to understand the role of potassium channels in ventricular fibrillation. J Intern Med. 2006;259(1):24–38
  26. Vincent GM. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death. Annu Rev Med. 1998;49:263–274
  27. Mohler PJ, Schott JJ, Gramolini AO, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature. 2003;421(6923):634–639
  28. Napolitano C, Priori S, Schwartz P. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA. 2005;294:2975–2980
  29. Kaufman S. Efficient genotyping for congenital long QT syndrome. JAMA. 2005;294:3027–3028
  30. Sanguinetti MC, Mitcheson JS. Predicting drug-HERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci. 2005;26(3):119–124
  31. Frustaci A, Priori SG, Pieroni M, et al. Cardiac histological substrate in patients with clinical phenotype of Brugada syndrome. Circulation. 2005;112(24):3680–3687
  32. Shimizu W. Acquired forms of the Brugada syndrome. J Electrocardiol. 2005;38(4 Suppl.):22–25
  33. George H, Jundi H, Walters N, et al. Arrhythmogenic mutation-linked defects in ryanodine receptor autoregulation reveal a novel mechanism of Ca2+ release channel dysfunction. Circ Res. 2005;
  34. Chimenti C, Pieroni M, Maseri A, Frustaci A. Histologic findings in patients with clinical and instrumental diagnosis of sporadic arrhythmogenic right ventricular dysplasia. JACC. 2005;43(12):2305–2313
  35. Drory Y, Turetz Y, Hiss Y, et al. Sudden unexpected death in persons less than 40 years of age. Am J Cardiol. 1991;68(13):1388–1392
  36. Doolan A, Langlois N, Semsarian C. Causes of sudden cardiac death in young Australians. Med J Aust. 2004;180(3):110–112
  37. Sechtem U, Mahrholdt H, Hager S, Vogelsberg H. New non-invasive approaches for the diagnosis of cardiomyopathy: magnetic resonance imaging. Ernst Schering Res Found Workshop. 2006;(55):261–285
  38. Kyto V, Saukko P, Lignitz E, et al. Diagnosis and presentation of fatal myocarditis. Hum Pathol. 2005;36(9):1003–1007
  39. Kytö V, Saukko P, Lignitz E, et al. Diagnosis and presentation of fatal myocarditis. Human Pathology. 2005;36(9):1003–1007
  40. Karch SB, Billingham ME. The pathology and etiology of cocaine-induced heart disease. Arch Pathol Lab Med. 1988;112(3):225–230
  41. Karch SB. Cocaine cardiovascular toxicity. South Med J. 2005;98(8):794–799
  42. Karle CA, Kiehn J. An ion channel ’addicted’ to ether, alcohol and cocaine: the HERG potassium channel. Cardiovasc Res. 2002;53(1):6–8
  43. Wong AS. Toxicogenetics. In:  Karch S editors. Drug abuse handbook. Boca Raton, Boston, London, New York: Taylor and Francis; 2006;
  44. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulationspecific dosages. Acta Psychiatr Scand. 2001;104(3):173–192
  45. Svenningsson P, Chergui K, Rachleff I, et al. Alterations in 5-HT1B Receptor Function by p11 in Depression-Like States. Science. 2006;311(January 6):77–81
  46. Priori SG, Napolitano C. Role of genetic analysis in cardiology: part I: mendelian disease: cardiac channelopathies. Circulation 2006 (February 28);113(8):1130–5.

PII: S1752-928X(07)00067-4

doi: 10.1016/j.jflm.2007.04.008

Journal of Forensic and Legal Medicine
Volume 14, Issue 7 , Pages 389-397 , October 2007

Article Tools

* Image Usage & Resolution